tirzepatide patient information for Medical Weight Loss Tirzepatide Patient Education Handouts: Weight

Grasas (lpidos) 0g

Ready to Explore Further

FDA approves Novo Nordisks oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults owenhaskins Oct 20, 2025 3 min read Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)

The technology we use is FDA-cleared and has a long-standing track record of helping people safely achieve their body contouring goals

Less than 1% opted for metabolic and bariatric surgery

The new weight-loss drugs have created a hope and optimism among my patients that I have frankly not seen before, says Sarah C